Siamab Therapeutics is a biopharmaceutical company developing novel cancer immunotherapies. Siamab has developed a platform of technologies that enable the rapid discovery and development of therapeutic antibodies that bind to a novel class of carbohydrate antigens present on cancer cells. The company’s lead program is in preclinical studies for the treatment of solid tumors.
February 5, 2014
Sialix Closes Oversubscribed Second Tranche of Series B Financing
January 24, 2014
Fierce Biotech interview with Jeff Behrens, Sialix CEO